PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
Sep 30, 2025 at 8:45 AM EDT
PETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dr. Shmuel Sharoni will present the topline results from the Company's successful Phase 3 SHIELD II trial of D-PLEX₁₀₀ at the upcoming 2025 American College of Surgeons (ACS) Clinical Congress in Chicago, IL.
Dr. Shmuel Sharoni will deliver a presentation titled "Efficacy Of A Novel Local Prolonged-release Incisional Doxycycline On Surgical Site Infection Prophylaxis In Abdominal Colorectal Surgery: The Shield II Phase 3 Randomized Clinical Trial," during the high-impact clinical trials session on Sunday, October 5, 2025, at 11:30 AM CT.
Conference Details:
2025 ACS Clinical Congress; October 4–7, McCormick Place, Chicago, IL
Presentation Date: Sunday, October 5, 2025, at 11:30 AM CT
Session: SF109 "High Impact Clinical Trials and Studies"